Vincerx Pharma, Inc.
VINC
$0.05
-$0.005-9.09%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -26.66% | -18.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -48.12% | -17.54% | |||
| Operating Income | 48.12% | 17.54% | |||
| Income Before Tax | 37.45% | -1.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 37.45% | -1.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 37.45% | -1.93% | |||
| EBIT | 48.12% | 17.54% | |||
| EBITDA | 48.21% | 17.57% | |||
| EPS Basic | 60.87% | 28.56% | |||
| Normalized Basic EPS | 44.08% | 50.01% | |||
| EPS Diluted | 60.87% | 28.56% | |||
| Normalized Diluted EPS | 44.08% | 50.01% | |||
| Average Basic Shares Outstanding | 59.85% | 42.67% | |||
| Average Diluted Shares Outstanding | 59.85% | 42.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||